IDHS SUPR

The federal Food and Drug Administration program pertains to the use of minors during tobacco sales compliance checks compensation and general program petty cash management. The Family Smoking Prevention and Tobacco Control Act amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) by, among other things, adding a new chapter granting the Food and Drug Administration (FDA) authority to regulate the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors. The Illinois FDA program allows for compliance monitoring of tobacco retail establishments across Illinois to assure that tobacco products are not sold to minors as defined by the Tobacco Control Act. The Illinois Department of Human Services Division of Substance Use Prevention and Recovery (IDHS SUPR) Contractor will serve as the provider for minor support services. The FDA program minor support services will include: payment of youth participant stipends; modest meal allowances for youth participants and/or for snacks if compliance checks are held after school; insurance coverage for the youth minors; and petty cash for purchasing tobacco products. Petty cash will be allocated based on the number of undercover buys. Vendor shall not perform services, provide supplies or incur expenses in amount exceeding the contract amount.

The Public Health Service Act and the Family Smoking Prevention and Tobacco Control Act, Public Law 111-31, 42 US Code 300u-3

N/A

21 CFR Part 1140 20 ILCS 301 Alcoholism and Other Drug Abuse and Dependency Act

The Family Smoking Prevention and Tobacco Control Act (TCA) provides the authority to regulate tobacco product manufacturing, distribution and marketing. Regulatory research will provide the scientific evidence to guide the implementation of this authority. Research areas include: 1) approaches that test the toxicity of tobacco smoke, aerosol, or specific constituents, 2) the effect of tobacco product characteristics on addiction and abuse liability, 3) the short and long term health effects of tobacco products, 4) understanding the knowledge, attitudes and behaviors related to tobacco product use, 5) understanding how to effectively communicate the health effects of tobacco products, 6) the influences of tobacco marketing, and 7) understanding the impact of potential FDA regulatory actions. The strategic priorities for these research areas can be found at https://www.fda.gov/tobacco-products/research/research-priorities

Yes

Reference terms in Part 3 of the UGA: program-specific terms and conditions.

Nonprofit Organizations;

Applicants should review the eligibility information in the individual funding opportunity announcements issued under this CFDA.

This Tobacco Control Regulatory Research Program will support research aimed at providing guidance and evidence to develop regulation for tobacco product manufacturing, distribution and marketing. The general public will ultimately benefit.

Direct Payments for Specific Use

Human Services

No Credentials or Documentation are required. This program is excluded from coverage under 2 CFR 200, Subpart E - Cost Principles.

Preapplication coordination is not applicable. Environmental impact information is not required for this program. This program is excluded from coverage under E.O. 12372.

2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program.

Funding decisions are based on scientific merit (42 CFR 52h) and program relevance. Scientific merit review encompasses: the peer review criteria detailed in the specific funding announcement, as well as the significance, approach, and innovation of the proposed research; the competency of the principal investigator; the adequacy of the resources and environment; the proposed budget and requested period of support; and, where applicable, the adequacy of the measures for protecting against adverse effects upon humans, animals, or the environment. Relevance to Tobacco Control Regulatory Research program priorities will also be taken into consideration.

All applications for research grants, cooperative agreements, training, and SBIR and STTR grants are evaluated for scientific and technical merit by an appropriate scientific peer review panel and by the National Advisory Council of the NIH Institute or Center that will manage the award. All competitive applications compete for available funds on the basis of scientific and technical merit, program relevance, and program balance. FDA Center for Tobacco Control will make final decisions on the relevance and program balance.

> 180 Days. Review the individual Funding Opportunity Announcement under this CFDA for any application-specific deadlines.

N/A

A principal investigator may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH homepage http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-064.html.

Renewal grants may only be submitted in response to a specific funding opportunity announcement under this CFDA.

Statutory formula is not applicable to this assistance listing. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.

(1) Research project grants provide support for clearly defined projects or a small group of related research activities, and when appropriate, support of research conferences; (2) program project and center grants support large-scale, broad-based programs of research, usually interdisciplinary, consisting of several projects with a common focus; (3) exploratory/development and clinical exploratory/developmental grants encourage the development of new research activities in categorical program areas; (4) cooperative agreements support single or a group of related research activities with significant involvement of federal staff; (5) small grants support newer, less experienced investigators; investigators at institutions without a well developed research tradition and resources; the testing of new methods or techniques; small-scale exploratory and pilot studies, or exploration of an unusual research opportunity; small grants provide research support of up to $50,000 direct costs per year for a period of up to 2 years; (6) research training grants including fellowships and institutional training grants, career development grants and loan repayment contracts; and (7) SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit and feasibility of proposed research or research and development efforts to determine the quality of performance of the small business grantees. Phase II grants are for the continuation of the research initiated in Phase I and that are likely to result in commercially viable products or processes. Only Phase I awardees are eligible to apply for Phase II support; STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application and the quality of performance of the small business concerns. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of the Phase II application.Research must directly support the Family Smoking Prevention and Tobacco Control Act and the Center for Tobacco Products, Food and Drug Administration Research Priorities found at https://www.fda.gov/tobacco-products/research/research-priorities

Periodic Financial Reports, Periodic Performance Reports, and Close out reports are required. Program Reports: Annual progress and financial status reports for continuing projects and final reports on all projects upon conclusion are required. Mid-period progress reports may be also be required or requested. Cash Reports: Not applicable. Progress Reports: Annual progress reports for continuing projects are required to assess progress. Mid-period progress reports may be also be required or requested. Expenditure Reports: Expenditure reports are applicable and will be submitted monthly on the SF425.

Not Applicable.

Expenditures and other financial records, and also administrative records, must be retained for 3 years from the day on which the grantee submits the last expenditure report for the grant period. Scientific data must be maintain to comply with Circular A-110 Shelby Amendment.

073344426490000NE FY25: Funded Program 0733.4426.4900.000000NE

Fiscal Year 2021: $146,500 Fiscal Year 2022: $119,161 Fiscal Year 2025: $119,161

Fiscal Year 2021: $146,500 - $146,500 Average: $146,500 Fiscal Year 2022: $119,161 - $119,161 Average: $119,161 Fiscal Year 2025: $119,161 - $119,161 Average: $119,161

Fiscal Year 2021: 1 award made.

45 CFR 74; 42 CFR 52; Guidelines are included in Funding Opportunity Announcements. Grants will be available under the authority of and administered in accordance with the NIH Grants Policy Statement and Federal regulations at 42 CFR Part 52 and 42 CFR Part 52a; Administrative requirements at 45 CFR Part 74.

None.

Division of Substance Use Prevention and Recovery 600 East Ash Street, Building 500, Third Floor Springfield, IL 62703

https://prevention.nih.gov/tobacco-regulatory-science-program

This Tobacco Control Regulatory Research Program will support research aimed at providing guidance and evidence to develop regulation for tobacco product manufacturing, distribution and marketing. The general public will ultimately benefit.

This Tobacco Control Regulatory Research Program will support research aimed at providing guidance and evidence to develop regulation for tobacco product manufacturing, distribution and marketing. The general public will ultimately benefit.

6/16/2012

FY 2024 : $119,161
FY 2025 : $119,161